SAN FRANCISCO, November 1, 2022 /PRNewswire/ — Dr. Nathan Pennell of the Cleveland Clinic Taussig Cancer Institute has joined Vial’s Oncology CRO Advisory Board. Dr Pennell will advise Flask on improving sound CRO in oncology products and services.
Nathan Pennell, MD, Ph.D., FASCO, is Professor of Medicine and Director of the Lung Cancer Medical Oncology Program at the Cleveland Clinic Taussig Cancer Institute. Dr. Pennell earned his Ph.D. in neuroscience and medicine University of FloridaFaculty of Medicine of Gainesville. He completed his residency in internal medicine at Brigham and Women’s Hospital, followed by postgraduate training at the Dana Farber Cancer Institute.
Dr. Pennell specializes in the care of patients with thoracic malignancies. His clinical research interests center on the development of novel cancer therapies, and he has contributed to over 280 publications. Dr Pennell is editor of the ASCO educational book, podcast publisher for the Journal of Practice in Oncologye, and to the editorial board of JAMA Oncology. Dr. Pennell is also associate associate director for clinical research at the Case Comprehensive Cancer Center.
“Vial has an ambitious mission to improve clinical trial processes through technology. The technology they create could improve trial efficiency, speeding the process of bringing treatments to market sooner. I am thrilled to serve as an advisor to their oncology CRO with the goal of helping cancer patients receive treatments earlier,” said Dr. Pennell on joining Vial’s Scientific Advisory Board.
Vial is a technology-focused CRO that provides industry-leading clinical trial management services that enable faster, more efficient trials for biotech sponsors. Vial CRO in oncology stands out for relying on digital technology, such as its Vial technology platform, which brings together eSource, EDC, eTMFand ePro, in a connected system to streamline site processes. These cutting-edge CRO services will accelerate the development of new treatments and devices for oncology sponsors and patients.
See the full version here.
About the bottle: Flask is a next-generation technology-based CRO that promises faster, higher-quality trial execution. The Vial Contract Research Organization (CRO) delivers on the promise of more efficient testing with its innovative technology platform that powers end-to-end testing. Vial operates in several therapeutic areas (CRO Dermatology, CRO in ophthalmology, CRO in oncology, Gastroenterology CROand CRO in neurology). The bottle is a San Francisco, Californiabased company.